![coronavirus]()
There are more than 2,000 registered trials for COVID-19 — with more new trials being registered on a daily basis — but researchers say a majority of those trials are lacking key features that would be crucial for determining potential treatments.
The studies will likely be inconclusive and require further research because of trial shortcomings which include no defined clinical endpoints to measure success, such as hospital discharge and survival, and a lack of the usual “blinding” strategy in which patients as well as medical professionals who assess outcomes are kept from knowing who received the treatment or placebo.
Source: Science Daily June 9, 2020